تسجيل الدخول/ اشتراك

The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain with US prices falling for GLP-1 treatments from Novo Nordisk and Eli Lilly

٠٢/٠٢ ٢٣:٤٠
صاعد
سبحة

تحديثات حية

الأخبار الشائعة